SEC Form 4 · accession 0001209191-19-015930
Protagonist Therapeutics, Inc · PTGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel R Saks
Officer — Chief Development Officer
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 6:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001377121
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2019 | A | 2,500 | $0.00 | A | 2,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $8.02 | Feb 28, 2019 | A | 15,000 | A | — | Feb 27, 2029 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date.
- F2The stock option vests in 48 equal monthly installments following the date of grant.